Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ADOCY | OTC Markets | USD | Delayed | |
ADOC | Paris | EUR | Real-time |
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Name | Age | Since | Title |
---|---|---|---|
Ekaterina Smirnyagina | 56 | 2013 | Independent Director |
Jay S. Skyler | 75 | 2016 | Chairman of Diabetes Medical Advisory Board |
Olivier Martinez | 52 | 2011 | Director |
Stephane Boissel | 54 | 2021 | Independent Director |
Gérard Soula | 78 | 2005 | Co-Founder & Chairman of the Board |
Olivier Soula | 53 | 2011 | Co-Founder, CEO & Director |
Denis Raccah | - | 2016 | Member of the Diabetes Medical Advisory Board |
Chantal Mathieu | - | 2016 | Member of the Diabetes Medical Advisory Board |
Steve Edelman | - | 2019 | Member of Global Diabetes Medical Advisory Board |
Vanita Aroda | - | 2016 | Member of the Diabetes Medical Advisory Board |
Bruce W. Bode | - | 2016 | Member of the Diabetes Medical Advisory Board |
Daniel Einhorn | - | 2016 | Member of the Diabetes Medical Advisory Board |
Carol Wysham | - | 2019 | Member of Global Diabetes Medical Advisory Board |
Alexander Zan Fleming | - | 2023 | Member of the Diabetes Medical Advisory Board |
Mads Dall | - | 2023 | Independent Director |
Tim Heise | - | 2023 | Member of the Diabetes Medical Advisory Board |
Thomas R. Pieber | - | 2023 | Member of the Diabetes Medical Advisory Board |
Matthew C. Riddle | - | 2023 | Member of the Diabetes Medical Advisory Board |
John B. Buse | - | 2016 | Member of the Diabetes Medical Advisory Board |
Vivian A. Fonseca | - | 2016 | Member of the Diabetes Medical Advisory Board |
Claudia Mitchell | - | 2021 | Independent Director |
Katherine S. Bowdish | 66 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review